Recent patient trials surrounding the medication Retatrutide , specifically the 120mg formulation branded as ZPHC, suggest a considerable benefit on body mass decrease and associated metabolic factors. Researchers anticipate that this dual agonist , influencing both GLP-1 and GIP receptors , may represent a major advance in the approach of obesity